Vertex stock rises on $3.33 billion second quarter sales
Published on 08/27/2026 at 11:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Vertex Pharmaceuticals Incorporated (US92532F1003) is trading on a fresh set of numbers after second-quarter revenue reached $3.33 billion and adjusted EPS came in at $4.73. The shares opened at $547.29 on August 27, 2026, while the market capitalization stood at $138.90 billion.
Revenue and guidance
Vertex reported second-quarter revenue of $3.33 billion, up 12 percent year over year, and lifted full-year 2026 revenue guidance to $13.1 billion-$13.2 billion from $12.95 billion-$13.1 billion. The same update also pointed to first-half cystic fibrosis product revenue of $6.1 billion, up 8.4 percent from the same period a year earlier.
That mix matters because the company is still leaning on cystic fibrosis for the bulk of sales while pushing newer products into the base. Non-CF products are expected to generate more than $500 million in 2026, a figure that implies growth of 185 percent year over year.
Pipeline and product mix
The near-term catalyst is the continuing shift from a single franchise to multiple revenue drivers, including Casgevy and Journavx. A June 2026 FDA filing for povetacicept in IgAN also keeps the renal program visible, with a decision expected on November 30, 2026.
In the second quarter, Alyftrek generated $573.6 million in sales, and the company said CF medicines produced $6.1 billion in the first half of 2026. The comparison is clear: total quarterly revenue rose 12 percent, while Alyftrek sales were one of the fastest-growing pieces of the mix.
What investors are watching
With the stock at $547.29 and the market value at $138.90 billion on August 27, 2026, the question is whether Vertex can keep expanding beyond cystic fibrosis without a slowdown in its core business. The current setup gives investors two dated markers to track: the raised $13.1 billion-$13.2 billion revenue view for 2026 and the November 30, 2026 FDA date for povetacicept.
Alyftrek remains central
Alyftrek is Vertex's newest cystic fibrosis medicine and a useful signal for how well the franchise can refresh itself. Its $573.6 million second-quarter contribution shows the company can still add volume inside the core business while broader non-CF products start to scale.
Price and setup
Vertex stock opened at $547.29 on August 27, 2026, with a market capitalization of $138.90 billion. The numbers leave the shares tied closely to execution on the raised 2026 outlook and on the next regulatory step in renal disease.
Company facts
Company: Vertex Pharmaceuticals Incorporated
ISIN: US92532F1003
Ticker: VRTX
Exchange: NASDAQ
Sector / Industry: Health Care / Biotechnology
Index membership: S&P 500
Price (as of August 27, 2026): $547.29 USD
Market cap: $138.90 billion
Next earnings date: November 5, 2026
